Biotherapeutics News and Research

RSS

Sartorius Stedim Biotech introduces new ambr 15 cell culture microbioreactor system

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, is introducing its new generation of ambr 15 cell culture automated microbioreactor system.

From Sartorius 3 May 2019

Celltrion and iProgen Biotech announce partnership for development of novel ADCs

On April 8, Celltrion and the Canada-based iProgen Biotech Inc. announced to agree to partner for the development of novel ADCs against validated antibody targets, including HER2 and CD20.

8 Apr 2019

Probing Submicron Protein Aggregation using Asymmetrical Flow Field-Flow Fractionation, AF4, and Light Scattering

The most recent developments by Wyatt in their instrumentation and software have made the full potential of FFF accessible to a wider user base. In this interview, Kim R. Williams and Christoph Johann talk to News-Medical and Life Sciences about the technologies and their research.

From Waters | Wyatt Technology 27 Mar 2019

Injection of genetically modified virus effectively treats metastatic melanoma patients

Injection of a genetically modified virus that induces the body's own immune cells to attack metastatic melanoma effectively treated almost 40 percent of patients with tumors that could not be surgically removed, according to researchers from three prominent cancer centers in a study published as an "article in press" on the Journal of the American College of Surgeons website in advance of print publication.

28 Jan 2019

RBSC announces partnership with Mitacs to develop and test yeast-based RNAi technology

Renaissance BioScience Corp., a leading global microorganism bioengineering company, is pleased to announce a new partnership with Mitacs, the University of British Columbia and the University of Manitoba for a three-year, Cdn$975,000 multi-investigator research and development project.

24 Jan 2019

Bio-Rad publishes new paper on generation, characterization of complex-specific antibodies

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, has published new findings on the generation and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.

From Bio-Rad Laboratories 11 Jan 2019

High-performing MS device reaches new level in characterizing protein impurities

In response to current regulatory guidance a Mass Spectrometry-based Host Cell Protein detection approach with faster, more accurate and wider-ranging detection is essential.

10 Jan 2019

MD Anderson Cancer Center and 4D pharma team up to evaluate live biotherapeutic oncology pipeline

The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D's live biotherapeutic oncology pipeline across a range of cancer settings.

7 Jan 2019

Stand Up to Cancer supports potential approach to more efficiently target pancreatic cancer

Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new immunotherapies, will receive $1 million in initial funding from Stand Up to Cancer.

21 Nov 2018

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.

23 Oct 2018

LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.

20 Sep 2018

Cancer Research UK invests £14 million to transform London into cancer biotherapeutics hub

The city of London will be transformed into a world leading hub for cancer biotherapeutics research and treatment, with a new £14 million investment from Cancer Research UK, announced today (Monday).

19 Sep 2018

New polyclonal immunotherapy successfully neutralizes Ebola virus

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided "100% protection against a lethal dose of the Ebola virus" in a recent animal study published in The Journal of Infectious Diseases.

15 Aug 2018

Oncolytic virus alerts the immune system to attack tumors

A new UC San Francisco study has shown that a cancer-killing virus currently in clinical trials may function as a cancer vaccine - in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus-infected region.

14 Feb 2018

UTokyo enters into agreement for developing personalized cancer vaccine

The University of Tokyo entered an agreement for developing a personalized cancer vaccine using a novel method involving the body's immune response.

25 Jan 2018

TGen awarded $2.5 million SU2C grant to test new method of treating pancreatic cancer

Stand Up To Cancer has awarded a $2.5 million SU2C CatalystR grant to the Translational Genomics Research Institute to investigate a revolutionary new method of treating pancreatic cancer, one of the most aggressive of all cancers.

13 Oct 2017

New cell therapy restores movement in people with paralyzing spinal cord injuries

Four of six people with paralyzing spinal cord injuries who were treated with a new cell therapy have recovered two or more motor levels on at least one side, new study results show.

6 Oct 2017

Nanomedical Diagnostics introduces new NTA biosensor for faster, reliable characterization of proteins

Nanomedical Diagnostics, a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of a new NTA biosensor chip for use with its label-free Agile R100 assay system.

26 Jul 2017

Pharmaceutical giant Roche funds concept study aiming to find cure for Angelman syndrome

A collaborative group of parent-driven organizations seeking a cure for Angelman syndrome has teamed up with F. Hoffmann-La Roche Ltd, one of the world’s largest pharmaceutical and diagnostics companies, in the first phase of a study that will support the design of human clinical trials and treatment development for the disorder.

28 Jun 2017

WHO to launch pilot project for prequalifying biosimilar cancer medicines

This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.

8 May 2017